Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on June 24, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Reg FD disclosure furnished under Item 7.01, with Section 18 liability protections.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure furnished under Item 7.01, with Section 18 liability protections
- Content excluded from incorporation by reference into other SEC filings absent explicit reference
Item 8.01 · Other Events
- Global workforce reduction of approximately 17% tied to expected completion of LOTIS-5 and LOTIS-7 trials
- Annualized cost savings estimated at approximately $10 million, supporting cash preservation
- One-time pre-tax restructuring charges of approximately $3 million, mostly recognized in Q2 2026
- Savings and charges remain uncertain, with potential for additional restructuring costs
- Execution remains linked to LOTIS-5 regulatory outcomes, ZYNLONTA revenue, debt obligations, and cash runway through at least 2028
Item EX-99.1 · Exhibit EX-99.1
- 17% workforce reduction targets approximately $10 million in annualized savings, improving flexibility but reducing organizational capacity
- Approximately $3 million in pre-tax severance charges, mostly recognized in Q2 2026
- FDA pre-sBLA meeting planned for August 2026; ZYNLONTA LOTIS-5 sBLA submission expected in Q4 2026
- LOTIS-7 data anticipated by end-2026, creating a key catalyst for earlier-line DLBCL expansion
- Expected cash runway extends at least into 2028, subject to loan-covenant liquidity requirements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.